We did take a little bit of pricing this year already. So we had the toric out there.
And we got kind of on our heels a little bit because of the MyDay production side of things. I guess just first question relative to our model, the SG&A spend was a bit higher than anticipated.
“Serving as President and CEO has been a privilege and I would like to thank all our employees for their commitment and dedication.
Ophthalmology. So, we have a number of lines coming in and bringing those lines forward by a month or two months or 2.5 months in some cases has pulled production from the latter part of this year and the beginning of '21 into '20 and even months earlier here in '20. | Privacy Policy | California Consumer Privacy Policy | Terms of Use | Legal and Modern Slavery Act | Sitemap, United Nations Sustainable Development Goals. Thanks. We're doing them a little differently. So we'll be able to look and see with some detail around, hey, where we most successful in the markets where we have salespeople, where we don't, how successful were we with the targeted marketing being on just cable versus being on national channels and so forth. Having said that, Asia-Pac is already rebounding and we expect growth in Q2, even in the face of the coronavirus. Opex was up 5.4% year-over-year, resulting in consolidated operating margins of 25%, down from 26.2% last year. You may proceed with your question.
Just two questions. I have the utmost confidence in him.”. Regarding financial expectations from MiSight, we're still forecasting roughly $10 million in sales this year, including $2 million in the U.S., and then $25 million in fiscal 2021 and around $50 million in fiscal 2022.
We've been fortunate and now we haven't had any employees infected by the virus that we're aware of. .gnw_table_border_collapse td.gnw_label, .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } And then we should be back to double-digit growth certainly in Q3 and Q4. Okay. I do think that if there is deferrals because of the coronavirus that we do pick that up, we didn't roll that into guidance, but I'm not sure why we wouldn't, right?
Thank you.
This quarter met expectations and we're now well positioned to deliver stronger results moving forward. Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Cooper Companies, Inc. Earnings Conference Call. About The Cooper CompaniesThe Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). With its headquarters in San Ramon, California, it has a workforce of more than 12,000 employees[2] and consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI) which manufactures medical devices and fertility and genomic products for the women’s health care market. Albert G. White III -- President & Chief Executive Officer. Matt O'Brien -- Piper Jaffray & Co. -- Analyst. The first year we hired a bunch of salespeople, we did ads on kind of all the TV stations, if you will, in the New York metro area, in Northern Cal.
I think it's actually more than China.
Our next question comes from Jeff Johnson with Baird.
Agostino Ricupati Chief Accounting Officer & Senior Vice President, Finance & Tax . The $15 million impact from coronavirus being a headwind, what is -- what's the offset then to be able to keep your growth rates for the full year unchanged? How do we think about other scenarios if there is something comparable where you had to adapt to a more regional or global potential slowdown? The most important aspect of our future success is remaining focused on our business objectives to stay positioned ahead of our competitors. Now they don't have to have a toric, but as docs have become better and better at understanding that and looking for astigmatisms and fitting patients with really truly the correct lens, a lot of times, more often than be it fit right now, that correct lens is a toric lens.
On MyDay, yeah, MyDay is solely a matter of getting production up and running faster.
Additionally, and more specifically to contact lenses, there is a continuing trade up from FRPs to dailies, the trade up from legacy hydrogel dailies to silicone hydrogel dailies, geographic expansion and growth in torics and multifocals. .gnw_table_border_collapse td.gnw_subhead, .gnw_subhead {font: 12px Arial; text-align: center; vertical-align: bottom;}
And then I'll have a couple of follow-ups. .gnw_table_border_collapse td.gnw_media_caption, .gnw_media_caption { font-size: 8pt; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-Regular } Everything will be fine, and kind of go fully back to normal. We are back at it there. It will be done by the -- by a professional that we have and then professionals at the universities who are there, making sure that the ECPs understand the clinical benefits and so forth, and the clinical trials and all the information behind it and why the lens worse, how it works, how to help them with any fitting questions or anything they may have. Yeah. But to your question and to your point, the legacy hydrogel business is continuing to decline. How do I get the parent comfortable that their eight-year-old can do this or with their nine-year-old or their 10-year-old can wear these lenses. For our effective tax rate, we're now forecasting the full year to be roughly 12%, which incorporates Q1 along with the updated regional profit estimates and benefits from existing share-based comp. You lowered 1% for the year.
Maybe at a high level, what does that certification program entail? Albert G. White III was named President and CEO of CooperCompanies in May 2018. Business Units. Brian G. Andrews -- Senior Vice President, Chief Financial Officer & Treasurer. If somebody has lenses at home, and for some reason, they are not going to get more, then they're going to ultimately need them. There were a number of that came that really wanted to be involved and wanted to get signed up early. Can you just talk a little bit about what's progressed since you updated people in January at the JPMorgan Conference? The prevalence of myopia is projected to increase from approximately two billion people worldwide in 2010 to almost five billion people in 20501, bringing with it near- and long-term health challenges. How does the interest level look or the backlog, if you would, beyond the first 1,800? So, unfortunately there hasn't been a lot of options for them there. Having said that, we will get a few million dollars out of that. Board of Directors.
And with that, I'll hand it back to the operator for questions. And I imagine DT1 toric will actually do fairly well when they come out with that product. If you look at fertility, it wasn't production delays in fertility. Thanks for taking the questions. We ship the product over there, obviously, but if demand pulled back there, we would take that product and reallocate it into the European market and the US.
We're not really seeing an impact outside of China.
Thank you. Overall for CooperSurgical, we expected this quarter to be our most challenging due to the tough 8% comp from a year ago and the Q4 PARAGARD buy-in, but we hit our expectations and remain confident in posting a strong year. This growth really demonstrates our strength with daily silicones and it bodes well for the future as MyDay capacity is quickly improving.
/*.gnw_table_border_collapse td {padding-left: 3px!important; padding-right: 3px!important;}*/
The 5% overall daily growth, it was slower than it's been quite a while.
Cumulative Growth of a $10,000 Investment in Stock Advisor, Cooper Companies Inc (COO) Q1 2020 Earnings Call Transcript @themotleyfool #stocks $COO, The Cooper Companies (COO) Q3 2020 Earnings Call Transcript, Cooper Companies Inc (COO) Q2 2020 Earnings Call Transcript, Cooper Companies Inc (COO) Q4 2019 Earnings Call Transcript, Cooper Companies Inc (COO) Q3 2019 Earnings Call Transcript, Cooper Companies Inc (COO) Q2 2019 Earnings Call Transcript, Copyright, Trademark and Patent Information. I know you also saw list pricing be increased by everybody this year. .gnw_table_border_collapse td.gnw_data_uline, .gnw_data_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} No question about it.
Instead of focusing images on the retina, images are focused at a point in front of the retina.
MiSight’s safety and effectiveness were studied in a three-year randomized, controlled clinical trial of 135 children who were ages 8 to 12 at the start of treatment and who used MiSight or a conventional soft contact lens. Given the variability with currencies, we've decided to use the same rates we used in December, including the euro at $1.10, the Yen at $1.09 and the pound at $1.29. It's pretty easy to walk out the door and buy product online if you're fitting someone in a sphere. We shouldn't go crazy on that because rates are moving around like crazy, earnings [Phonetic] moving around like crazy, but just to be clear on that. .gnw_table_border_collapse td.gnw_num_ulinetop, .gnw_num_ulinetop {font: 12px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; border-top: solid black 1.0pt;} Yeah, with the coronavirus, we're assuming everything gets back to normal kind of in May. Since 1980, we've been making eye contact lenses for astigmatism, nearsightedness, farsightedness, and more–all with your health and comfort in mind. Sure. We are all highly confident in Al's ability to lead Cooper's including our 2018 Guidance and all statements regarding acquisitions including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and diluted earnings per share are forward looking. Our limitation is that we have seven of the top colleges doing the training. CooperConnect is an avenue for sharing and learning as well as an internal communications tool to connect and engage employees worldwide.
And our adjusted leverage ratio moved slightly lower to 1.82 times. Thank you. So we're looking at our own pricing right now. .gnw_border_right_double {border-right: double black 3px !important;}
Larry Biegelsen -- Wells Fargo -- Analyst. Good questions and good discussion today, so thank you very much. We'll look at incremental pricing and any adjustments to rebates as we kind of move through the year here. So we've seen those come back already in February. You will see that start to improve a little bit in Q2, but definitely improve quite a bit more for Q3 and Q4. Copyright West LLC. Thank you very much, and nice to be talking with you. So having that product out and being able to talk about it and just continue to talk about Biofinity is great, it helps the entire family. And with that, I will turn the call over to Brian. You're correct -- so it was $0.38 up to $0.78 so it was a positive $0.40.
Our presenters on today's call are Al White, President and Chief Executive Officer; and Brian Andrews, Chief Financial Officer and Treasurer.